Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC38 | CAL-101 | 2 | 72 | 0.001 | 3075.8 | 3073.0 | 690.5 | -3.0 | 1.000 | 1.000 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 0.0032 | 3088.8 | 3073.0 | 690.5 | -2.49 | 1.000 | 1.010 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 0.01 | 2962.3 | 3073.0 | 690.5 | -2.0 | 0.966 | 0.964 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 0.032 | 3149.8 | 3073.0 | 690.5 | -1.49 | 1.020 | 1.020 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 0.1 | 3062.0 | 3073.0 | 690.5 | -1.0 | 0.997 | 0.996 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 0.32 | 3061.5 | 3073.0 | 690.5 | -0.495 | 0.997 | 0.996 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 1.0 | 2843.0 | 3073.0 | 690.5 | 0.0 | 0.929 | 0.925 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | CAL-101 | 2 | 72 | 3.2 | 2692.3 | 3073.0 | 690.5 | 0.505 | 0.881 | 0.876 | 2.154 | HCC38 CAL101 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.001 | 2094.3 | 3106.8 | 690.5 | -3.0 | 0.668 | 0.674 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.0032 | 2022.0 | 3106.8 | 690.5 | -2.49 | 0.641 | 0.651 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.01 | 2005.0 | 3106.8 | 690.5 | -2.0 | 0.634 | 0.645 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.032 | 1979.3 | 3106.8 | 690.5 | -1.49 | 0.625 | 0.637 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.1 | 1997.8 | 3106.8 | 690.5 | -1.0 | 0.632 | 0.643 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 0.32 | 1974.8 | 3106.8 | 690.5 | -0.495 | 0.623 | 0.636 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 1.0 | 1894.0 | 3106.8 | 690.5 | 0.0 | 0.592 | 0.610 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Everolimus | 2 | 72 | 3.2 | 1863.8 | 3106.8 | 690.5 | 0.505 | 0.580 | 0.600 | 2.170 | HCC38 Everolimus 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.001 | 2725.8 | 2985.8 | 690.5 | -3.0 | 0.916 | 0.913 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.0032 | 3120.5 | 2985.8 | 690.5 | -2.49 | 1.040 | 1.050 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.01 | 2991.8 | 2985.8 | 690.5 | -2.0 | 1.000 | 1.000 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.032 | 3075.0 | 2985.8 | 690.5 | -1.49 | 1.030 | 1.030 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.1 | 2874.3 | 2985.8 | 690.5 | -1.0 | 0.964 | 0.963 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 0.32 | 2593.8 | 2985.8 | 690.5 | -0.495 | 0.871 | 0.869 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 1.0 | 2220.5 | 2985.8 | 690.5 | 0.0 | 0.738 | 0.744 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | Pictilisib | 2 | 72 | 3.2 | 1918.0 | 2985.8 | 690.5 | 0.505 | 0.622 | 0.642 | 2.112 | HCC38 GDC0941 0 2 72 |
HCC38 | GDC-0980 | 2 | 72 | 0.001 | 3094.3 | 3084.3 | 690.5 | -3.0 | 1.000 | 1.000 | 2.159 | HCC38 GDC0980 0 2 72 |